K G Parhofer

Summary

Affiliation: University of Munich
Country: Germany

Publications

  1. ncbi request reprint [Effect of glucose control on lipid levels in patients with type 2 diabetes]
    K G Parhofer
    Medizinische Klinik II, Grosshadern, Klinikum der Ludwig Maximilians Universität München, Germany
    Dtsch Med Wochenschr 127:958-62. 2002
  2. ncbi request reprint Effect of pioglitazone on lipids in well controlled patients with diabetes mellitus type 2 -- results of a pilot study
    K G Parhofer
    Department of Internal Medicine II, Grosshadern, Ludwig Maximilians University, Munich, Germany
    Exp Clin Endocrinol Diabetes 113:49-52. 2005
  3. ncbi request reprint Increase in adiponectin levels during pioglitazone therapy in relation to glucose control, insulin resistance as well as ghrelin and resistin levels
    C Otto
    Medical Department 2, Grosshadern, University Hospital of Munich, Marchioninistrasse 15, D 81377 Munich, Germany
    J Endocrinol Invest 29:231-6. 2006
  4. ncbi request reprint Influence of etofibrate on LDL-subtype distribution in patients with diabetic dyslipoproteinemia
    H C Geiss
    Department of Internal Medicine II, Grosshadern, University of Munich, Munich, Germany
    Exp Clin Endocrinol Diabetes 111:322-4. 2003
  5. ncbi request reprint Beyond LDL-cholesterol: HDL-cholesterol as a target for atherosclerosis prevention
    K G Parhofer
    Department of Internal Medicine II, Klinikum Grosshadern, Ludwig Maximilians University, Munich, Germany
    Exp Clin Endocrinol Diabetes 113:414-7. 2005
  6. ncbi request reprint [Cushing's syndrome with bilateral nodular adrenal enlargement]
    M op den Winkel
    Medizinische Klinik II, Universitätsklinikum München Grosshadern, Marchioninistr 15, 81377 Munchen
    Internist (Berl) 48:870-3. 2007
  7. ncbi request reprint Liquid chromatography tandem-mass spectrometry (LC-MS/MS)--technique and applications in endocrinology
    M Vogeser
    Institute of Clinical Chemistry, Hospital of the University of Munich, Munich, Gemany
    Exp Clin Endocrinol Diabetes 115:559-70. 2007
  8. ncbi request reprint [Diabetic dyslipidemia: which target levels and treatment options exist for diabetics?]
    U C Broedl
    Medizinische Klinik und Poliklinik II, Campus Grosshadern, Munchen
    MMW Fortschr Med 150:41-3. 2008
  9. ncbi request reprint [Homocysteine--CRP--lipoprotein (a). When do you evaluate the "new" risk factors]
    K G Parhofer
    Medizinischen Klinik II, Klinikum Grosshadern der LMU München
    MMW Fortschr Med 143:22-4. 2001
  10. doi request reprint [Operative techniques and outcomes in metabolic surgery: sleeve gastrectomy]
    T P Hüttl
    Chirurgische Klinik und Poliklinik, Klinikum der Universitat Munchen Grosshadern, Munchen, Germany
    Zentralbl Chir 134:24-31. 2009

Collaborators

Detail Information

Publications36

  1. ncbi request reprint [Effect of glucose control on lipid levels in patients with type 2 diabetes]
    K G Parhofer
    Medizinische Klinik II, Grosshadern, Klinikum der Ludwig Maximilians Universität München, Germany
    Dtsch Med Wochenschr 127:958-62. 2002
    ..In this study we evaluated whether an improvement of the lipid status can also be observed in a routine clinical setting. Furthermore, we evaluated how many patients achieve lipid target levels by improving glucose control...
  2. ncbi request reprint Effect of pioglitazone on lipids in well controlled patients with diabetes mellitus type 2 -- results of a pilot study
    K G Parhofer
    Department of Internal Medicine II, Grosshadern, Ludwig Maximilians University, Munich, Germany
    Exp Clin Endocrinol Diabetes 113:49-52. 2005
    ..It is unclear whether different antidiabetic strategies differ in their effects on the lipid profile. Particularly, it is unknown whether glitazones improve lipid values independently of their effects on glucose metabolism...
  3. ncbi request reprint Increase in adiponectin levels during pioglitazone therapy in relation to glucose control, insulin resistance as well as ghrelin and resistin levels
    C Otto
    Medical Department 2, Grosshadern, University Hospital of Munich, Marchioninistrasse 15, D 81377 Munich, Germany
    J Endocrinol Invest 29:231-6. 2006
    ....
  4. ncbi request reprint Influence of etofibrate on LDL-subtype distribution in patients with diabetic dyslipoproteinemia
    H C Geiss
    Department of Internal Medicine II, Grosshadern, University of Munich, Munich, Germany
    Exp Clin Endocrinol Diabetes 111:322-4. 2003
    ....
  5. ncbi request reprint Beyond LDL-cholesterol: HDL-cholesterol as a target for atherosclerosis prevention
    K G Parhofer
    Department of Internal Medicine II, Klinikum Grosshadern, Ludwig Maximilians University, Munich, Germany
    Exp Clin Endocrinol Diabetes 113:414-7. 2005
    ....
  6. ncbi request reprint [Cushing's syndrome with bilateral nodular adrenal enlargement]
    M op den Winkel
    Medizinische Klinik II, Universitätsklinikum München Grosshadern, Marchioninistr 15, 81377 Munchen
    Internist (Berl) 48:870-3. 2007
    ..This surgical approach (bilateral adrenalectomy) has been the standard way of treatment for AIMAH until the new concept of the ectopic receptors was developed...
  7. ncbi request reprint Liquid chromatography tandem-mass spectrometry (LC-MS/MS)--technique and applications in endocrinology
    M Vogeser
    Institute of Clinical Chemistry, Hospital of the University of Munich, Munich, Gemany
    Exp Clin Endocrinol Diabetes 115:559-70. 2007
    ....
  8. ncbi request reprint [Diabetic dyslipidemia: which target levels and treatment options exist for diabetics?]
    U C Broedl
    Medizinische Klinik und Poliklinik II, Campus Grosshadern, Munchen
    MMW Fortschr Med 150:41-3. 2008
  9. ncbi request reprint [Homocysteine--CRP--lipoprotein (a). When do you evaluate the "new" risk factors]
    K G Parhofer
    Medizinischen Klinik II, Klinikum Grosshadern der LMU München
    MMW Fortschr Med 143:22-4. 2001
    ..An increase in these parameters should prompt the early use of lipid-lowering drugs or aspirin. In exceptional cases only (homocysteine), correction of the risk factors should be considered...
  10. doi request reprint [Operative techniques and outcomes in metabolic surgery: sleeve gastrectomy]
    T P Hüttl
    Chirurgische Klinik und Poliklinik, Klinikum der Universitat Munchen Grosshadern, Munchen, Germany
    Zentralbl Chir 134:24-31. 2009
    ..Laparoscopic sleeve gastrectomy is no longer an experimental procedure. It should be accepted as one of the effective standard procedures for surgical treatment of morbid obesity...
  11. ncbi request reprint Efficacy of different low-density lipoprotein apheresis methods
    K G Parhofer
    Medical Department II, Klinikum Grosshadern, Ludwig Maximilians University, Munich, Germany
    Ther Apher 4:382-5. 2000
    ..Therefore, the decision of which system should be used in a given patient must be individualized taking the pre-apheresis LDL concentration, concomitant pharmacotherapy, and fibrinogen concentration into account...
  12. ncbi request reprint Atorvastatin improves postprandial lipoprotein metabolism in normolipidemlic subjects
    K G Parhofer
    Department of Internal Medicine II, Klinikum Grosshadern, Ludwig Maximilians University, Munich, Germany
    J Clin Endocrinol Metab 85:4224-30. 2000
    ....
  13. ncbi request reprint Influence of atorvastatin versus simvastatin on fibrinogen and other hemorheological parameters in patients with severe hypercholesterolemia treated with regular low-density lipoprotein immunoadsorption apheresis
    C Otto
    Medical Department II, Klinikum Grosshadern, University of Munich, Germany
    Ther Apher 4:244-8. 2000
    ..Therefore, with respect to hemorheology, we conclude that atorvastatin should not be withheld from hypercholesterolemic patients regularly treated with LDL immunoadsorption...
  14. ncbi request reprint Lipoprotein (a) metabolism estimated by nonsteady-state kinetics
    K G Parhofer
    Department of Internal Medicine II, Klinikum Grosshadern, Ludwig Maximilians University, Munich, Germany
    Lipids 34:325-35. 1999
    ..Thus, despite the limitations arising from the assumptions implicit to this method, metabolic parameters of Lp(a) can be estimated from the rebound of plasma concentration following apheresis...
  15. ncbi request reprint Low density lipoprotein apolipoprotein B metabolism: comparison of two methods to establish kinetic parameters
    K G Parhofer
    Department of Internal Medicine II, Klinikum Grosshadern, Ludwig Maximilians University, Munich, Germany
    Atherosclerosis 144:159-66. 1999
    ....
  16. doi request reprint How will new medications affect the lipoprotein apheresis situation in Germany?
    K G Parhofer
    Medical Department II, Grosshadern, University Munich, Marchioninistrase 15, 81377 Munich, Germany
    Atheroscler Suppl 14:71-2. 2013
    ..If proven to be safe, these drugs may significantly reduce the necessity for regular lipid apheresis since more patients will achieve LDL-cholesterol treatment targets by drug therapy alone...
  17. pmc Suppression of the nuclear factor Eny2 increases insulin secretion in poorly functioning INS-1E insulinoma cells
    P Dames
    Medizinische Klinik II, Ludwig Maximilians Universitat, München 80336, Germany
    Exp Diabetes Res 2012:460869. 2012
    ..Whether these findings extend to other experimental conditions or to in vivo physiology needs to be determined in further studies...
  18. doi request reprint Less advanced stages of colon cancer in patients with type 2 diabetes mellitus: an unexpected finding?
    J M Nagel
    Medizinische Klinik und Poliklinik II, Klinikum der Universitat Munchen, Grosshadern, LMU Munchen, Germany
    Exp Clin Endocrinol Diabetes 120:224-8. 2012
    ..e., metastasized disease (UICC III and IV), at the time of diagnosis, since such a finding may have an impact on future guidelines for patients with T2DM...
  19. ncbi request reprint [Therapy of hyperlipoproteinemia in the elderly]
    K G Parhofer
    Medizinische Klinik II, Grosshadern, Klinikum der Ludwig Maximilians Universität München
    Internist (Berl) 44:968-76. 2003
    ..e. a LDL-cholesterol below 100 mg/dl should be achieved. In hyper- or dyslipoproteinemic patients without evidence of clinical or subclinical atherosclerosis cholesterol lowering drugs should be used restrictively...
  20. ncbi request reprint In vivo metabolism of LDL subfractions in patients with heterozygous FH on statin therapy: rebound analysis of LDL subfractions after LDL apheresis
    H C Geiss
    Department of Internal Medicine II, Grosshadern, University of Munich, Munich, Germany
    J Lipid Res 45:1459-67. 2004
    ..Thus, our data indicate that in statin-treated patients with heterozygous FH dense LDLs originate from two sources. Whether this is also valid in other metabolic situations (with predominant small, dense LDLs) remains to be determined...
  21. doi request reprint Irbesartan has no short-term effect on insulin resistance in hypertensive patients with additional cardiometabolic risk factors (i-RESPOND)
    K G Parhofer
    Medizinische Klinik II, Grosshadern, Klinikum der Universitaet, Munich, Germany
    Int J Clin Pract 64:160-8. 2010
    ..Intervention studies have shown that angiotensin receptor blockers (ARB) may reduce the incidence of type 2 diabetes mellitus. It is currently unclear whether short-term therapy with ARBs affects metabolic parameters...
  22. doi request reprint In Germany diabetic patients with coronary artery disease are treated more intensively than diabetic patients with other manifestations of atherothrombosis--results from the REACH registry
    K G Parhofer
    Department of Internal Medicine II, Grosshadern, Ludwig Maximilians University, Munich, Germany
    Exp Clin Endocrinol Diabetes 118:51-6. 2010
    ..It is unknown whether diabetics with CAD differ from those with other manifestations of atherothrombosis such as CVD or PAD regarding clinical characteristics, biochemical parameters, or medications...
  23. ncbi request reprint Short-term therapy with atorvastatin or fenofibrate does not affect plasma ghrelin, resistin or adiponectin levels in type 2 diabetic patients with mixed hyperlipoproteinaemia
    C Otto
    Medical Department 2 Grosshadern, University Hospital Munich, Marchioninistrasse 15, D 81377, Munich, Germany
    Acta Diabetol 44:65-8. 2007
    ..In patients with type 2 diabetes and mixed hyperlipoproteinaemia, short-term atorvastatin as well as fenofibrate therapy had no significant effects on adiponectin, ghrelin or resistin levels...
  24. ncbi request reprint Defining high-fat-diet rat models: metabolic and molecular effects of different fat types
    R Buettner
    Department of Internal Medicine I, University of Regensburg, 93042 Regensburg, Germany
    J Mol Endocrinol 36:485-501. 2006
    ..Diets based on LC-SFA and MUFA induced hepatic steatosis with SREBP1c activation. This points to an intact transcriptional hepatic insulin effect despite resistance to insulin's metabolic actions...
  25. ncbi request reprint [Glinides and glitazones in diabetes treatment. Are they really effective?]
    K G Parhofer
    Medizinische Klinik II Grosshadern, Klinikum der Ludwig Maximilians Universität München
    MMW Fortschr Med 144:34-6, 38-9. 2002
    ..Both groups of substances are a useful addition to the antidiabetic drug armamentarium. Endpoint studies involving these substances have, however, not yet been performed...
  26. ncbi request reprint Effects of ezetimibe on plasma lipoproteins in severely hypercholesterolemic patients treated with regular LDL-apheresis and statins
    H C Geiss
    Medical Department I, University Mainz, Mainz, Germany
    Atherosclerosis 180:107-12. 2005
    ..Thus, in patients with severe LDL-hypercholesterolemia and CHD the addition of ezetimibe to intensive lipid lowering therapy (statins and LDL-apheresis) resulted in a further, clinically significant decrease of LDL-cholesterol...
  27. ncbi request reprint Cholesterol, essential fatty acids, and suicide
    Jurgen Brunner
    Max Planck Institute of Psychiatry, Kraepelinstrasse 10, 80804 Munich, Germany de
    Pharmacopsychiatry 35:1-5. 2002
    ..Increasing the dietary intake of omega-3 fatty acids may increase central serotonergic activity and reduce impulsive and aggressive behaviours...
  28. ncbi request reprint Extracorporal low-density lipoprotein elimination by immunoadsorption
    M M Ritter
    Medizinische Klinik, Klinikum Ibbenbüren, Ibbenbüren, Germany
    Ther Apher Dial 7:370-2. 2003
    ..It is based on affinity chromatography. As with other apheresis techniques, immunoadsorption has specific advantages and disadvantages. These have to be taken into account when selecting an apheresis technique for the individual patient...
  29. ncbi request reprint Influence of simvastatin on LDL-subtypes in patients with heterozygous familial hypercholesterolemia and in patients with diabetes mellitus and mixed hyperlipoproteinemia
    H C Geiss
    Department of Internal Medicine II, Klinikum Grosshadern, University of Munich, Germany
    Exp Clin Endocrinol Diabetes 110:182-7. 2002
    ..However, the relative reduction of individual LDL-subtypes differed between both groups. This suggests that the effect of simvastatin on LDL-subtype distribution depends on the type of underlying hyperlipoproteinemia...
  30. ncbi request reprint Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia
    R J Frost
    Department of Internal Medicine II, Klinikum Grosshadern, Ludwig-Maximilians University, Munich, Germany
    Am J Cardiol 87:44-8. 2001
    ..We conclude that atorvastatin and fenofibrate can improve lipoprotein metabolism in type 2 diabetes. However, the medications affect different aspects of lipoprotein metabolism...
  31. ncbi request reprint Parameters of childhood obesity and their relationship to cardiovascular risk factors in healthy prepubescent children
    H C Geiss
    Ludwig-Maximilians-University Munich, Klinikum Grosshadern, Medical Department II, Marchioninstr. 15, 81377 Munich, Germany
    Int J Obes Relat Metab Disord 25:830-7. 2001
    ..The BMI may be superior to the PI as the association between BMI and cardiovascular risk factors is less affected by gender...
  32. ncbi request reprint Effect of atorvastatin on low-density lipoprotein subtypes in patients with different forms of hyperlipoproteinemia and control subjects
    H C Geiss
    Department of Internal Medicine II, Klinikum Grosshadern, University of Munich, Munich, Germany
    Metabolism 50:983-8. 2001
    ..However, the relative reduction of individual LDL subtypes differed between these groups. This finding suggests that the effect of atorvastatin on LDL subtype distribution depends on the type of underlying hyperlipoproteinemia...
  33. ncbi request reprint Short-term effects of statin therapy in patients with hyperlipoproteinemia after liver transplantation: results of a randomized cross-over trial
    R Zachoval
    Medical Department II, Klinikum Grosshadern, Ludwig-Maximilians-University, Munich, Germany
    J Hepatol 35:86-91. 2001
    ..CONCLUSIONS: Low-dose cerivastatin and pravastatin significantly improve lipid profiles following liver transplantation without affecting liver function or immunosuppression...
  34. ncbi request reprint Novel mutation (Gly280Ala) in the ATP-binding domain of glycerol kinase causes severe hyperglycerolemia
    T Wibmer
    Physiological Chemistry, Adolf Butenandt Institute, University of Munich, Germany
    Exp Clin Endocrinol Diabetes 113:396-403. 2005
    ..This mutation is assumed to destabilize a hydrogen bond between ligand and enzyme resulting in a reduced activity of glycerol kinase and therefore in hyperglycerolemia...
  35. ncbi request reprint [Polycystic ovary syndrome and metabolic syndrome]
    C J Auernhammer
    Medizinische Klinik II Grosshadern, Klinikum der Ludwig Maximilians Universität München, Germany
    Dtsch Med Wochenschr 127:971-7. 2002
  36. ncbi request reprint Effect of atorvastatin on lipid parameters, LDL subtype distribution, hemorrheological parameters and adhesion molecule concentrations in patients with hypertriglyceridemia
    K Empen
    Medical Department II, Ludwig Maximilians University, Munich, Germany
    Nutr Metab Cardiovasc Dis 13:87-92. 2003
    ..We hypothesised that some of these risk markers might be beneficially influenced by lipid-lowering therapy with atorvastatin in hypertriglyceridemic patients...